利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Crystalline forms of quetiapine hemifumarate
    3.
    发明申请
    Crystalline forms of quetiapine hemifumarate 审中-公开
    喹硫平半富马酸盐的结晶形式

    公开(公告)号：US20100016579A1

    公开(公告)日：2010-01-21

    申请号：US12455947

    申请日：2009-06-08

    申请人： Revital Lifshitz-Liron ,  Eti Kovalevski-Ishai ,  Ben-Zion Dolitzky ,  Shlomit Wizel ,  Rami Lidor-Hadas

    发明人： Revital Lifshitz-Liron ,  Eti Kovalevski-Ishai ,  Ben-Zion Dolitzky ,  Shlomit Wizel ,  Rami Lidor-Hadas

    IPC分类号： C07D417/04

    CPC分类号： C07D281/16

    摘要： The present invention relates to novel crystalline forms of quetiapine hemifumarate, denominated quetiapine hemifumarate form II and quetiapine hemifumarate form III. These novel crystalline forms of quetiapine hemifumarate have been characterized by methods including x-ray powder diffraction (XRD), Fourier transform IR spectroscopy (FTIR), differential scanning calorimetry (DSC), and thermal gravimetric analysis (TGA). Methods for preparation of the novel crystalline quetiapine hemifumarate form II as its chloroform solvate and its dichloromethane solvate, form III as its chloroform solvate, and form I are provided.

    摘要翻译： 本发明涉及喹硫平半富马酸盐的新型结晶形式，称为喹喔啉半富马酸盐形式II和喹硫平半富马酸盐形式III。 已经通过X射线粉末衍射（XRD），傅立叶变换红外光谱（FTIR），差示扫描量热法（DSC）和热重分析（TGA）等方法对这些新型的喹硫平半富马酸盐结晶形态进行了表征。 提供了形成II型作为其氯仿溶剂合物的新型结晶喹硫平半富马酸盐及其二氯甲烷溶剂合物，形式III为其氯仿溶剂合物和形式I的方法。

    Processes for preparing calcium salt forms of statins
    6.
    发明授权
    Processes for preparing calcium salt forms of statins 失效
    制备他汀类钙盐形式的方法

    公开(公告)号：US06777552B2

    公开(公告)日：2004-08-17

    申请号：US10222556

    申请日：2002-08-16

    申请人： Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Rami Lidor-Hadas

    发明人： Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Rami Lidor-Hadas

    IPC分类号： C07D207325

    CPC分类号： C07D207/34 ,  C07D209/24 ,  C07D213/55 ,  C07D215/14 ,  C07D239/42 ,  C07D309/30 ,  C07D405/06 ,  Y02P20/55

    摘要： Processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected statin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide.

    摘要翻译： 提供了通过使用氢氧化钙从他汀类的酯衍生物或被保护的酯衍生物制备他汀类钙盐的方法。 将酯或保护的酯衍生物与氢氧化钙接触以获得钙盐。 优选的他汀类是瑞舒伐他汀，匹伐他汀和阿托伐他汀，辛伐他汀和洛伐他汀。 在以受保护的他汀类酯衍生物开始的方法中，保护基在与氢氧化钙接触的盐形成过程中水解，或者与酸催化剂接触，然后与氢氧化钙接触。